Atara Biotherapeutics Inc (NASDAQ: ATRA)’s stock price has dropped by -23.97 in relation to previous closing price of 16.19. Nevertheless, the company has seen a loss of -31.61% in its stock price over the last five trading days. zacks.com reported 2025-01-08 that Here, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move.
Is It Worth Investing in Atara Biotherapeutics Inc (NASDAQ: ATRA) Right Now?
The stock has a 36-month beta value of 0.46. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ATRA is 4.31M, and at present, short sellers hold a 12.38% of that float. On January 15, 2025, the average trading volume of ATRA was 116.37K shares.
ATRA’s Market Performance
ATRA stock saw an increase of -31.61% in the past week, with a monthly gain of 4.77% and a quarterly increase of 53.30%. The volatility ratio for the week is 18.89%, and the volatility levels for the last 30 days are 13.76% for Atara Biotherapeutics Inc (ATRA). The simple moving average for the past 20 days is -7.28% for ATRA’s stock, with a 6.44% simple moving average for the past 200 days.
Analysts’ Opinion of ATRA
Many brokerage firms have already submitted their reports for ATRA stocks, with Mizuho repeating the rating for ATRA by listing it as a “Neutral.” The predicted price for ATRA in the upcoming period, according to Mizuho is $1 based on the research report published on November 09, 2023 of the previous year 2023.
ATRA Trading at 0.04% from the 50-Day Moving Average
After a stumble in the market that brought ATRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.84% of loss for the given period.
Volatility was left at 13.76%, however, over the last 30 days, the volatility rate increased by 18.89%, as shares surge +12.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.50% upper at present.
During the last 5 trading sessions, ATRA fell by -31.61%, which changed the moving average for the period of 200-days by -29.66% in comparison to the 20-day moving average, which settled at $13.28. In addition, Atara Biotherapeutics Inc saw -7.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATRA starting from Henrich Jill, who sale 1,000 shares at the price of $11.20 back on Nov 18 ’24. After this action, Henrich Jill now owns 19,378 shares of Atara Biotherapeutics Inc, valued at $11,198 using the latest closing price.
Hyllengren Eric J, the EVP, CFO and COO of Atara Biotherapeutics Inc, sale 1,364 shares at $11.20 during a trade that took place back on Nov 18 ’24, which means that Hyllengren Eric J is holding 23,392 shares at $15,274 based on the most recent closing price.
Stock Fundamentals for ATRA
Current profitability levels for the company are sitting at:
- -1.19 for the present operating margin
- 0.83 for the gross margin
The net margin for Atara Biotherapeutics Inc stands at -9.59. The total capital return value is set at 9.02. Equity return is now at value -2014.86, with -80.34 for asset returns.
Based on Atara Biotherapeutics Inc (ATRA), the company’s capital structure generated -1.23 points at debt to capital in total, while cash flow to debt ratio is standing at -1.9. The debt to equity ratio resting at -0.55. The interest coverage ratio of the stock is -25.09.
Currently, EBITDA for the company is -266.0 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 0.74. The receivables turnover for the company is 75.24for trailing twelve months and the total asset turnover is 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.59.
Conclusion
To sum up, Atara Biotherapeutics Inc (ATRA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
